Comet assay reveals no genotoxicity risk of cationic solid lipid nanoparticles
Article first published online: 15 NOV 2013
Copyright © 2013 John Wiley & Sons, Ltd.
Journal of Applied Toxicology
Volume 34, Issue 4, pages 395–403, April 2014
How to Cite
Doktorovova, S., Silva, A. M., Gaivão, I., Souto, E. B., Teixeira, J. P. and Martins-Lopes, P. (2014), Comet assay reveals no genotoxicity risk of cationic solid lipid nanoparticles. J. Appl. Toxicol., 34: 395–403. doi: 10.1002/jat.2961
- Issue published online: 29 JAN 2014
- Article first published online: 15 NOV 2013
- Manuscript Revised: 9 OCT 2013
- Manuscript Accepted: 9 OCT 2013
- Manuscript Received: 3 AUG 2013
- Comet assay;
- solid lipid nanoparticles;
Cationic solid lipid nanoparticles (cSLN) are colloidal carriers for genes or drugs, particularly lipophilic drugs. Several reports exist on their high efficiency, but only a few studies report the effect of cSLNs on living cells. In the present work, internalization, cell viability (alamar blue assay) and genotoxic potential (alkaline comet assay) of three cSLN formulations (A–C) were evaluated in HepG2 and Caco-2 cells. cSLN showed an average hydrodynamic diameter (z-ave) of 141–222 nm, zeta-potential of 55.0–72.5 mV and polidispersity indices (PdI) of 0.336–0.421. Dispersion in physiological buffers increased z-ave and PdI. 0.01 mg ml–1 cSLN unaffected cell viability, but 1.0 mg ml–1 significantly decreased it, being cSLN-C (Compritol-based) the most toxic and HepG2 the most affected. DNA damage was not significantly increased by 0.1 mg ml–1 cSLN but damage was observed at 1.0 mg ml–1 cSLN-C. Thus, no genotoxicity is to be expected at concentrations that do not reduce cell viability. Copyright © 2013 John Wiley & Sons, Ltd.